{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:57:32Z","timestamp":1783191452930,"version":"3.54.6"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20148"],"award-info":[{"award-number":["20148"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"FIRC-AIRC","doi-asserted-by":"publisher","award":["IG-2017 \u2013 ID 20148"],"award-info":[{"award-number":["IG-2017 \u2013 ID 20148"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009888","name":"Regione Toscana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003980","name":"Istituto Toscano Tumori","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.phrs.2021.105965","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T18:26:04Z","timestamp":1635704764000},"page":"105965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in E\u03bc-TCL1 mice through the JNK\/STAT4\/p66Shc axis"],"prefix":"10.1016","volume":"174","author":[{"given":"Francesca","family":"Vanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Lopresti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Zurli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kabanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sicuranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Gemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M.","family":"Zisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Campiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosima T.","family":"Baldari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Butini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ulivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105965_bib1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105965_bib2","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1080\/10428194.2019.1646910","article-title":"For CLL cells, there\u2019s no place like home","volume":"60","author":"Lampson","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phrs.2021.105965_bib3","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/cancers12041006","article-title":"P66shc: a pleiotropic regulator of b cell trafficking and a gatekeeper in chronic lymphocytic leukemia","volume":"12","author":"Patrussi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2021.105965_bib4","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2021.105965_bib5","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1007\/s00018-019-03058-9","article-title":"Abnormalities in chemokine receptor recycling in chronic lymphocytic leukemia","volume":"76","author":"Patrussi","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.phrs.2021.105965_bib6","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105965_bib7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: from genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.105965_bib8","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3324\/haematol.2018.195396","article-title":"Updates on the hematologic tumor microenvironment and its therapeutic targeting","volume":"104","author":"Forte","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2021.105965_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.10.015","article-title":"SnapShot: chronic lymphocytic leukemia","volume":"32","author":"ten Hacken","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2021.105965_bib10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2021.105965_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11864-020-0715-5","article-title":"Novel therapies in chronic lymphocytic leukemia: a rapidly changing landscape","volume":"21","author":"Iovino","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.phrs.2021.105965_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-0881-4","article-title":"Revolution of chronic lymphocytic leukemia therapy: the chemo-free treatment paradigm","volume":"22","author":"Scheffold","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"7","key":"10.1016\/j.phrs.2021.105965_bib13","doi-asserted-by":"crossref","first-page":"IJH09","DOI":"10.2217\/ijh-2018-0010","article-title":"Current trends in the management of Richter\u2019s syndrome","volume":"7","author":"Allan","year":"2018","journal-title":"Int. J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2021.105965_bib14","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1182\/blood-2017-03-775858","article-title":"Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia","volume":"130","author":"Zurli","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105965_bib15","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1182\/blood-2007-12-130856","article-title":"The proapoptotic and antimitogenic protein p66SHC acts as a negative regulator of lymphocyte activation and autoimmunity","volume":"111","author":"Finetti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105965_bib16","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1182\/blood-2009-08-239244","article-title":"Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia","volume":"115","author":"Capitani","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105965_bib17","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2012-04-425959","article-title":"S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis","volume":"120","author":"Capitani","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105965_bib18","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3324\/haematol.2018.209981","article-title":"P66Shc deficiency in the E\u03bc-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape","volume":"104","author":"Patrussi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2021.105965_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1124\/mol.105.021204","article-title":"Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines","volume":"70","author":"Mulligan","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2021.105965_bib20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00280-009-1200-9","article-title":"Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells","volume":"66","author":"Nathwani","year":"2010","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.phrs.2021.105965_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejmech.2018.11.004","article-title":"Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents","volume":"162","author":"Brindisi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105965_bib22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bcp.2008.10.008","article-title":"The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells","volume":"77","author":"Bright","year":"2009","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.phrs.2021.105965_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4161\/cbt.11.4.14183","article-title":"Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro","volume":"11","author":"Forde","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phrs.2021.105965_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3892\/ijo.2016.3518","article-title":"The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells","volume":"49","author":"Nathwani","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2021.105965_bib25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/15384047.2015.1078028","article-title":"Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells","volume":"17","author":"Fiore","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phrs.2021.105965_bib26","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.7150\/jca.16616","article-title":"Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines","volume":"7","author":"Greene","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.phrs.2021.105965_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10637-016-0331-1","article-title":"The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; Suggested mechanism of action of PBOX-15","volume":"34","author":"Kinsella","year":"2016","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.phrs.2021.105965_bib28","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.1158\/0008-5472.CAN-09-0131","article-title":"The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia","volume":"69","author":"McElligott","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105965_bib29","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/sj.bjc.6605670","article-title":"Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo","volume":"102","author":"Bright","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2021.105965_bib30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/sj.cdd.4401997","article-title":"p66SHC promotes T cell apoptosis by inducing mitochondrial dysfunction and impaired Ca2+ homeostasis","volume":"14","author":"Pellegrini","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.phrs.2021.105965_bib31","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.4049\/jimmunol.1001391","article-title":"p66Shc is a negative regulator of Fc\u03b5RI-dependent signaling in mast cells","volume":"186","author":"Ulivieri","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2021.105965_bib32","doi-asserted-by":"crossref","first-page":"57086","DOI":"10.18632\/oncotarget.10977","article-title":"Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells","volume":"7","author":"Cattaneo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2021.105965_bib33","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1038\/sj.onc.1203481","article-title":"Serine phosphorylation of STATs","volume":"19","author":"Decker","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2021.105965_bib34","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105965_bib35","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2010-03-275180","article-title":"The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E\u03bc-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling","volume":"116","author":"Suljagic","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105965_bib36","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PPO.0000000000000416","article-title":"Targeted therapy in chronic lymphocytic leukemia","volume":"25","author":"Kipps","year":"2019","journal-title":"Cancer J."},{"key":"10.1016\/j.phrs.2021.105965_bib37","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/cancers12030642","article-title":"Precision medicine management of chronic lymphocytic leukemia","volume":"12","author":"Moia","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2021.105965_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.beha.2016.08.007","article-title":"The chronic lymphocytic leukemia microenvironment: beyond the B-cell receptor","volume":"29","author":"Choi","year":"2016","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.phrs.2021.105965_bib39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbamcr.2015.07.009","article-title":"Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment","volume":"1863","author":"ten Hacken","year":"2016","journal-title":"Biochim. Biophys. Acta - Mol. Cell Res."},{"key":"10.1016\/j.phrs.2021.105965_bib40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/bloodadvances.2020003423","article-title":"Overcoming resistance to targeted therapies in chronic lymphocytic leukemia","volume":"5","author":"Sk\u00e5nland","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.phrs.2021.105965_bib41","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2020007039","article-title":"Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL","volume":"137","author":"Agathangelidis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105965_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000175","article-title":"From biology to therapy: the CLL success story","volume":"3","author":"Yosifov","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.phrs.2021.105965_bib43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/bcp.12624","article-title":"Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo","volume":"80","author":"Bates","year":"2015","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2021.105965_bib44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/15384047.2016.1139245","article-title":"Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105","volume":"17","author":"Bates","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phrs.2021.105965_bib45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/46311","article-title":"The p66shc adaptor protein controls oxidative stress response and life span in mammals","volume":"402","author":"Migliaccio","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105965_bib46","doi-asserted-by":"crossref","first-page":"20930","DOI":"10.1038\/srep20930","article-title":"CJun N-terminal kinase (JNK) phosphorylation of serine 36 is critical for p66Shc activation","volume":"6","author":"Khalid","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105965_bib47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4161\/cc.4.3.1550","article-title":"The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence","volume":"4","author":"Klein","year":"2005","journal-title":"Cell Cycle"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821005491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821005491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:40:53Z","timestamp":1762353653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821005491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":47,"alternative-id":["S1043661821005491"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105965","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in E\u03bc-TCL1 mice through the JNK\/STAT4\/p66Shc axis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105965"}}